EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, **Alan Boobis**

Organisation/Company: Imperial College London

Country: United Kingdom

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

I consulted for and served as an expert witness in the USA for a group of attorneys, which originally included Arent Fox LLP (Par Pharmaceuticals Inc & Par Pharmaceutical Companies Inc); DuaneMorris LLP (Wockhardt); Vinson & Elkins LLP (Impax Laboratories Inc); Winston & Strawn LLP (Actavis South Atlantic LLC & Actavis Inc); Brinks Hofer Gilson & Lione (Watson Pharmaceuticals Inc, Watson Laboratories Incs, Watson Pharam Inc) in a patent dispute involving Nuedexta (dextromethorphan/quindine combination), used for dermatitis, emotional lability and a number of neurological orders in human patients. This consultancy was from July 2011 - Sept 2013. The issue related to a beneficial drug-drug interaction between the two components of the preparation.
I am currently a member of the Board of Trustees of the Health and Environment Sciences Institute Branch (HESI) of the International Life Sciences Institute (ILSI); chair of the Board of Trustees of ILSI; vice-president of the European Branch of ILSI. These organizations are not for profit. They are funded in part by unrestricted funds from pharmaceutical companies.
I was a member of the Scientific Advisory Board of the EU-Framework funded projects HEROIC and PEDICT-IV until 2014. I was chair the Scientific Advisory Board Innovative Medicines Initiative (IMI) project Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury until 2016. These projects included some pharmaceutical companies as partners. I received no remuneration. I am a member of the Scientific Advisory Board (non-remunerated) of the Swiss Centre for Applied Human Toxicology and of the Long Range Research Strategy (LRSS) Scientific Advisory Board, Cosmetics Europe (2017-date) (non-remunerated).
I was academic supervisor for a PhD student supported by an MRC-CASE studentship with GSK, from Oct 2011 to Oct 2015. The project was on the mitochondrial toxicity of drugs.
I was a member of the Phase I Protocol Review Board of the NIHR/Wellcome Trust Imperial Clinical Research Facility, where I provide input on toxicological issues, until June 2017.
Members of the Department of Medicine, Imperial College London, where I am employed, provide advice to and conduct research supported by pharmaceutical companies. None of these staff is under my management.
I a member of the British Pharmacology Society, the British Toxicology Society, the Royal Society of Biology, the European Society of Toxicologists (EUROTOX) and the US Society of Toxicology.
I chair the UK Committee on the Toxicity of Chemicals in Food, Consumer Products and the Environment (COT). I am regularly a member/chair of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) dealing with residues of veterinary drugs and of the Joint FAO/WHO Meeting on Pesticide Residues (JMPR).

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.

- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Alan Raymond Boobis	03/12/17
Date:	2017-12-03	

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template